The patients with non-valvular atrial fibrillation (NVAF), both permanent and paroxysmal, and history of previous transient ischemic attack (TIA) or stroke represent a category of patients at high risk of new embolic events, independently of the presence of other risk factors. In these patients, national and international guidelines recommend oral anticoagulants as first choice for antithrombotic prevention. Direct oral anticoagulants (DOACs) have been demonstrated to be not inferior to warfarin for many end points in NVAF patients in terms of efficacy and safety. The post hoc analysis in selected subgroups of patients enrolled in the three mega trials of phase III comparing DOACs (RE-LY, ROCKET-AF and ARISTOTLE) with warfarin help to evaluate whether superiority and non-inferiority persist in these subgroups. Here, patients with NVAF and history of previous TIA/stroke receiving DOACs as secondary prevention are compared with patients with the same characteristics receiving warfarin. An analysis of these patients has been recently published (separately for each of three DOACs). This analysis shows that DOACs maintain their non-inferiority when compared with warfarin in secondary prevention, representing a real alternative in this context of patients at high risk for ischemic and bleeding events. ©Copyright L. Masotti et al., 2013.
|Data di pubblicazione:||2013|
|Titolo:||Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation|
|Rivista:||ITALIAN JOURNAL OF MEDICINE|
|Digital Object Identifier (DOI):||10.4081/itjm.2013.s8.8|
|Codice identificativo Scopus:||2-s2.0-84902194332|
|Parole Chiave:||Apixaban; Atrial fibrillation; Dabigatran; Prophylaxis; Rivaroxaban; Stroke; Warfarin; Medicine (all)|
|Appare nelle tipologie:||Articolo su Rivista|